Samsung Biologics to provide CDMO support for ‘bio-venture’ firm GI Innovation

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/Manjurul)
(Image: Getty/Manjurul)

Related tags: Samsung biologics, GI Innovation, CDMO, Cell line development, phase I

Samsung Biologics is providing contract development services for GI Innovation’s pipeline, with the first among five molecules to initiate development immediately, says company representative.

The companies last week signed the contract for immune-chemotherapy at the Samsung Biologics headquarters in Seoul, South Korea.

Also headquartered in Seoul, GI Innovation – described as “bio-venture company” – is developing new drugs through the combination of microbiome and protein drugs, according to the company.

1
Samsung BioLogics CEO Tae Han Kim and GI Innovation CEO Soo Yeon Nam.

This is the second contract GI Innovation has signed with Samsung Biologics since launching their first project with together in June of last year, according to a Samsung Biologics representative.

The agreement is part of a multi-project deal that will see Samsung Biologics provide a range of services including cell line, process, and analytical method development. The company also will manufacture materials for the Phase I clinical trial and will support IND filing support for GI’s drug pipeline.

“Through the partnership, the first among five molecules will initiate development immediately, and overall SBL [Samsung Biologics] will develop two of GI’s projects per year,”​ the representative explained.

GI Innovation CEO Soo Yeon Nam said in a press release: "Thanks to Samsung BioLogics' CDMO business, we can overcome the problem of producing high-quality clinical test samples, the biggest barrier of bio venture companies.

"We are very positive that global pharmaceutical companies interested in the R&D pipeline of GI Innovation will be able to access global new drug licensing (BLA) and biotech drug business through Samsung BioLogics' CDMO service,”​ she added. “Through this collaboration, we wish to demonstrate the win-win model of venture firms and large corporations that the people and the government want."

‘One-stop service’

According to the Samsung Biologics representative, “The number of biotech companies focused on R&D discovery of novel biologics are constantly increasing in the market, and thus the need to outsource development services is growing rapidly.”

The company launched its contract development business in 2018 and has since secured new projects with eight domestic and overseas companies, including GI Innovation, the representative explained, citing its ability to provide “one-stop service” as one of the greatest benefits to working with the company.

“Altogether, our strength is providing integrated biologics development and manufacturing services at one-site, as a true one-stop service provider,” ​they said.

Related news

Show more

Related products

show more

What to consider when working with CRFs

What to consider when working with CRFs

Formedix | 21-Sep-2020 | Technical / White Paper

For a study to be successful, data collected must be correct and complete. To be correct and complete, forms must be well planned with meticulous attention...

Innovations in OSD

Innovations in OSD

Recorded the 06-Oct-2020 | Webinar

This DFE series of educational webinars looks at innovations in Oral Solid Dose Forms with the emergence of advanced technologies such as Continuous Manufacturing...

Register for free

Lessons Learned: Clinical Trials During a Pandemic

Lessons Learned: Clinical Trials During a Pandemic

PCM TRIALS | 01-Sep-2020 | Technical / White Paper

In a recent survey of clinical trial professionals (including pharmaceutical sponsors, CROs, site representatives and vendors), respondents reported that...

Related suppliers

Follow us

Products

View more

Webinars